Inspyr Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 04:40 pm
Share
Inspyr Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 156,000 compared to USD 115,000 a year ago. Net income was USD 17.156 million compared to net loss of USD 1.175 million a year ago. Basic earnings per share from continuing operations was USD 0.03 compared to basic loss per share from continuing operations of USD 0.23 a year ago. For the half year, operating loss was USD 346,000 compared to USD 240,000 a year ago. Net loss was USD 3.479 million compared to USD 1.901 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.54 a year ago.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
